These lawsuits assert legal theories, including: Trademark infringement Violating the corporate practice of medicine doctrine False advertising Unfair competition Violations of federal drug laws (misbranding, unapproved new drugs) FDA Enforcement On February 6, 2026, FDA announced its intent to use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns. The FDA explicitly announced steps to combat compounding pharmacies making these marketing claims: Compounded products are generic versions of FDA-approved drugs Compounded products are the same as FDA-approved drugs Compounded products use the same active ingredient as FDA-approved drugs Compounded products are clinically proven to produce results FDA has made clear that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. This means the agency may bypass traditional warning letter procedures
In addition, cytoskeleton dynamics are critical
Hydrapharm's Unbreakable not only contains BPC-157 but also includes Cissus quadrangularis and Andrographis paniculata (andrographolide)
The OOS flag reflects what the vendor's website displayed
Biophys Chem
ORLANDO Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies so widely, Daniel J
